Immunomedics Inc patents

Therapy of small-cell lung cancer (sclc) with a topoisomerase-i inhibiting antibody-drug conjugate (adc) targeting trop-2

The present invention relates to treatment of sclc with therapeutic adcs comprising a drug attached to an anti-trop-2 antibody or antigen-binding antibody fragment. Preferably, the drug is sn-38. ... Immunomedics Inc

Chimeric and humanized anti-histone antibodies

The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific cdr sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein. ... Immunomedics Inc

Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies

The present invention concerns compositions and methods of use of anti-hla-dr antibodies or fragments thereof. In preferred embodiments, the antibodies are subcutaneously administered to a human patient with a hematologic cancer or autoimmune disease. ... Immunomedics Inc

Antibody-sn-38 immunoconjugates with a cl2a linker

The present invention concerns improved methods and compositions for preparing sn-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the sn-38 is attached to the antibody or antibody fragment using a cl2a linker, with 1-12, more preferably 6-8, alternatively 1-5 sn-38 moieties per antibody or antibody fragment. ... Immunomedics Inc

Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells

Described herein are compositions and methods of use of anti-trop-2 antibodies or antigen-binding fragment thereof to isolate, enrich, detect, diagnose and/or characterize circulating tumor cells (ctcs) from patients with a trop-2 positive cancer. Preferably, the antibody is an rs7, 162-46.2 or mab650 antibody. ... Immunomedics Inc

Rs7 antibodies

This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. ... Immunomedics Inc

Antibody-sn-38 immunoconjugates with a cl2a linker

The present invention concerns improved methods and compositions for preparing sn-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the sn-38 is attached to the antibody or antibody fragment using a cl2a linker, with 1-12, more preferably 6 or less, most preferably 1-5 sn-38 moieties per antibody or antibody fragment. ... Immunomedics Inc

Anti-histone therapy in acute kidney injury

Acute kidney injury (aki) is often associated with damage to remote organs, such as lungs or heart. Aki induces kidney tubular necrosis as well as netosis, programmed neutrophil death leading to neutrophil extracellular traps (nets). ... Immunomedics Inc

Novel anti-pd-1 checkpoint inhibitor antibodies that block binding of pd-l1 to pd-1

The present invention concerns compositions and methods of use of anti-pd-1 antibodies comprising cdr sequences corresponding to seq id no:1 to seq id no:6. Preferably the antibody is a humanized antibody comprising the variable region amino acid sequences of seq id no: 9 and seq id no:10. ... Immunomedics Inc

Chimeric and humanized anti-histone antibodies

The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific cdr sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein. ... Immunomedics Inc

Efficacy of anti-hla-dr antibody drug conjugate immu-140 (hl243-cl2a-sn-38) in hla-dr positive cancers

The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an anti-hla-dr antibody or antigen-binding antibody fragment. The immunoconjugate may be administered at a dosage of between 3 mg/kg and 18 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg, more preferably 8, 10 or 12 mg/kg. ... Immunomedics Inc

Fusion proteins containing recombinant cytotoxic rnases

Recombinant immunotoxins containing a cytotoxic rnase fused to an antibody or antibody fragment may be produced in mammalian cell culture. Surprisingly, immunotoxins containing a cytotoxic rnase fused to the n-terminus of one antibody variable domain can be prepared and retain the ability to specifically bind antigen. ... Immunomedics Inc

Crosslinking of cd22 by epratuzumab triggers bcr signaling and caspase-dependent apoptosis in hematopoietic cancer cells

Extensive crosslinking of cd22 by plate-immobilized epratuzumab induced intracellular changes in daudi cells similar to ligating b-cell antigen receptor (bcr) with a sufficiently high amount of anti-igm. Either treatment leads to phosphorylation of cd22, cd79a and cd79b, along with their translocation to lipid rafts, both of which were needed to induce caspase-dependent apoptosis. ... Immunomedics Inc

Methods of treating cancer with antibodies that target the insulin-like growth factor type i receptor (igf-1r)

The present invention provides compositions and methods of use of anti-igf-1r antibodies or antibody fragments. Preferably the antibodies bind to igf-1r but not ir; are not agonists for igf-1r; do not block binding of igf-1 or igf-2 to isolated igf-1r, but effectively neutralize activation of igf-1r by igf-1 in intact cells; and block binding of an r1 antibody to igf-1r. ... Immunomedics Inc